105
Participants
Start Date
July 23, 2019
Primary Completion Date
October 31, 2025
Study Completion Date
May 31, 2027
Acalabrutinib
100mg capsule, PO, BD
Cyclophosphamide
750mg/m\^2, IV bolus
Doxorubicin
50mg/m\^2, IV bolus
Vincristine
1.4mg/m\^2, IV infusion
Prednisolone
40mg/m\^2, PO, OD
Rituximab
375mg/m\^2, IV infusion
RECRUITING
Belfast City Hospital, Belfast
RECRUITING
Royal Bournemouth Hospital, Bournemouth
RECRUITING
University Hospital of Wales, Cardiff
RECRUITING
Beatson West of Scotland Cancer Centre, Glasgow
RECRUITING
St James's University Hospital, Leeds
RECRUITING
Leicester Royal Infirmary, Leicester
RECRUITING
King's College Hospital, London
RECRUITING
St Bartholomew's Hospital, London
RECRUITING
University College London Hospital, London
RECRUITING
Christie Hospital, Manchester
RECRUITING
Norfolk and Norwich University Hospital, Norwich
RECRUITING
Nottingham City Hospital, Nottingham
RECRUITING
Churchill Hospital, Oxford
RECRUITING
Derriford Hospital, Plymouth
RECRUITING
Royal Hallamshire Hospital, Sheffield
RECRUITING
Southampton General Hospital, Southampton
Collaborators (1)
Bloodwise
OTHER
Acerta Pharma, LLC
OTHER
University of Birmingham
OTHER